Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Genetic variants in TGF-β pathway are associated with ovarian cancer risk.

Yin J, Lu K, Lin J, Wu L, Hildebrandt MA, Chang DW, Meyer L, Wu X, Liang D.

PLoS One. 2011;6(9):e25559. doi: 10.1371/journal.pone.0025559. Epub 2011 Sep 30.

2.

SNPs in the TGF-β signaling pathway are associated with increased risk of brain metastasis in patients with non-small-cell lung cancer.

Li Q, Wu H, Chen B, Hu G, Huang L, Qin K, Chen Y, Yuan X, Liao Z.

PLoS One. 2012;7(12):e51713. doi: 10.1371/journal.pone.0051713. Epub 2012 Dec 17.

3.

Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response.

Liang D, Meyer L, Chang DW, Lin J, Pu X, Ye Y, Gu J, Wu X, Lu K.

Cancer Res. 2010 Dec 1;70(23):9765-76. doi: 10.1158/0008-5472.CAN-10-0130. Epub 2010 Nov 30.

4.

Genetic variations in the transforming growth factor beta pathway as predictors of bladder cancer risk.

Wei H, Kamat AM, Aldousari S, Ye Y, Huang M, Dinney CP, Wu X.

PLoS One. 2012;7(12):e51758. doi: 10.1371/journal.pone.0051758. Epub 2012 Dec 12.

5.

Genetic variants of ADAM17 are implicated in the pathological process of Kawasaki disease and secondary coronary artery lesions via the TGF-β/SMAD3 signaling pathway.

Peng Q, Deng Y, Yang X, Leng X, Yang Y, Liu H.

Eur J Pediatr. 2016 May;175(5):705-13. doi: 10.1007/s00431-016-2696-8. Epub 2016 Feb 1.

PMID:
26833052
6.

Genetic variations in apoptosis pathway and the risk of ovarian cancer.

Xie H, Tao W, Wu X, Gu J.

Oncotarget. 2016 Aug 30;7(35):56737-56745. doi: 10.18632/oncotarget.10772.

7.

Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.

Wang D, Kanuma T, Mizunuma H, Takama F, Ibuki Y, Wake N, Mogi A, Shitara Y, Takenoshita S.

Cancer Res. 2000 Aug 15;60(16):4507-12.

8.

Associations between genetic variants in the TGF-β signaling pathway and breast cancer risk among Hispanic and non-Hispanic white women.

Boone SD, Baumgartner KB, Baumgartner RN, Connor AE, Pinkston CM, John EM, Hines LM, Stern MC, Giuliano AR, Torres-Mejia G, Brock GN, Groves FD, Kerber RA, Wolff RK, Slattery ML.

Breast Cancer Res Treat. 2013 Sep;141(2):287-97. doi: 10.1007/s10549-013-2690-z. Epub 2013 Sep 14.

9.

Genetic variants in telomere-maintenance genes are associated with ovarian cancer risk and outcome.

Sun Y, Tao W, Huang M, Wu X, Gu J.

J Cell Mol Med. 2017 Mar;21(3):510-518. doi: 10.1111/jcmm.12995. Epub 2016 Nov 7.

10.

Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk.

Kaklamani VG, Baddi L, Liu J, Rosman D, Phukan S, Bradley C, Hegarty C, McDaniel B, Rademaker A, Oddoux C, Ostrer H, Michel LS, Huang H, Chen Y, Ahsan H, Offit K, Pasche B.

Cancer Res. 2005 Apr 15;65(8):3454-61. Erratum in: Cancer Res. 2006 Mar 15;66(6):3345.

11.

Genetic variants in the fibroblast growth factor pathway as potential markers of ovarian cancer risk, therapeutic response, and clinical outcome.

Meng QH, Xu E, Hildebrandt MA, Liang D, Lu K, Ye Y, Wagar EA, Wu X.

Clin Chem. 2014 Jan;60(1):222-32. doi: 10.1373/clinchem.2013.211490. Epub 2013 Oct 21.

12.

Transforming growth factor-beta signaling pathway in patients with Kawasaki disease.

Shimizu C, Jain S, Davila S, Hibberd ML, Lin KO, Molkara D, Frazer JR, Sun S, Baker AL, Newburger JW, Rowley AH, Shulman ST, Burgner D, Breunis WB, Kuijpers TW, Wright VJ, Levin M, Eleftherohorinou H, Coin L, Popper SJ, Relman DA, Fury W, Lin C, Mellis S, Tremoulet AH, Burns JC.

Circ Cardiovasc Genet. 2011 Feb;4(1):16-25. doi: 10.1161/CIRCGENETICS.110.940858. Epub 2010 Dec 2. Erratum in: Circ Cardiovasc Genet. 2011 Apr;4(2):e9. Davila, Sonia [removed].

13.

Common genetic variation in IGF1, IGFBP1 and IGFBP3 and ovarian cancer risk.

Terry KL, Tworoger SS, Gates MA, Cramer DW, Hankinson SE.

Carcinogenesis. 2009 Dec;30(12):2042-6. doi: 10.1093/carcin/bgp257.

14.

Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer.

Lin M, Stewart DJ, Spitz MR, Hildebrandt MA, Lu C, Lin J, Gu J, Huang M, Lippman SM, Wu X.

Carcinogenesis. 2011 Jul;32(7):1050-6. doi: 10.1093/carcin/bgr067. Epub 2011 Apr 22.

15.

Stepwise approach to SNP-set analysis illustrated with the Metabochip and colorectal cancer in Japanese Americans of the Multiethnic Cohort.

Cologne J, Loo L, Shvetsov YB, Misumi M, Lin P, Haiman CA, Wilkens LR, Le Marchand L.

BMC Genomics. 2018 Jul 9;19(1):524. doi: 10.1186/s12864-018-4910-8.

16.

[Association of three single nucleotide polymorphisms of the E-cadherin gene with susceptibility to epithelial ovarian carcinoma].

Liang J, Li Y, Wang N.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008 Apr;25(2):183-6. Chinese.

PMID:
18393242
17.

Polymorphisms in TGF-beta1 gene and the risk of lung cancer.

Kang HG, Chae MH, Park JM, Kim EJ, Park JH, Kam S, Cha SI, Kim CH, Park RW, Park SH, Kim YL, Kim IS, Jung TH, Park JY.

Lung Cancer. 2006 Apr;52(1):1-7. Epub 2006 Feb 24.

PMID:
16499994
18.

Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer.

Yang H, Dinney CP, Ye Y, Zhu Y, Grossman HB, Wu X.

Cancer Res. 2008 Apr 1;68(7):2530-7. doi: 10.1158/0008-5472.CAN-07-5991.

19.

Polymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancers.

Jin Q, Hemminki K, Grzybowska E, Klaes R, Söderberg M, Zientek H, Rogozinska-Szczepka J, Utracka-Hutka B, Pamula J, Pekala W, Försti A.

Int J Cancer. 2004 Oct 20;112(1):94-9.

20.

Gene-gene interactions between TGF-β/Smad3 signalling pathway polymorphisms affect susceptibility to knee osteoarthritis.

Su SL, Yang HY, Lee HS, Huang GS, Lee CH, Liu WS, Wang CC, Peng YJ, Lai CH, Chen CY, Lin C, Pan YT, Salter DM, Chen HC.

BMJ Open. 2015 Jun 11;5(6):e007931. doi: 10.1136/bmjopen-2015-007931.

Supplemental Content

Support Center